The joint venture has resulted in the independent company JAGUAHR Therapeutics, which will focus on developing aryl hydrocarbon receptor antagonists for cancer treatment.
Tagrisso, a small molecule inhibitor drug, has been approved in China as a first-line treatment for patients with non-small cell lung tumors bearing specific mutations.
Singapore researchers have discovered that cancer stem cells consume the amino acid methionine much faster than it can be generated, and this vulnerability could be exploited for cancer treatment.
ASLAN Pharmaceuticals will focus on clinical development of varlitinib while BioGenetics will obtain the necessary regulatory approvals for the use of the drug in South Korea.
Using bispecific T-cell engager technology, or BiTE, researchers in Japan have found that the cancer-killing activity of T-cells in tumors can be estimated from T-cells in the blood.
A research group has found that Chinese who consumed larger amounts of onions and garlic had a lower risk of being diagnosed with colorectal cancer.